Croatia, Pharma and Corruption - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Croatia, Pharma and Corruption
Croatia is on track to join the EU in 2013 and offers a well-developed pharmaceutical market. However, its EU membership application has undergone much scrutiny because of concerns regarding corruption, organised crime and counterfeit pharmaceuticals.

Pharmaceutical Technology Europe
Volume 23, Issue 8


1. BBC News, "Croatia cleared for EU membership in 2013" (UK, 2011)., accessed 30 June 2011.

2. Business Monitor, Croatia Pharmaceuticals and Healthcare Report Q3 (UK, May 2011).

3. ANZAG, "ANZAG: Result under pressure" press release (Germany, 2011), accessed 30 June 2011.

4. Epsicom, The Outlook for Pharmaceuticals in Central & Eastern Europe (UK, April 2011).

5. L. Voncina and T. Strizrep, Eurohealth 16 (4), 20–22 (2011).

6. L. Voncina "Croatian 2009–2010 pharma reform", Ekonom:east Media Group, online (Serbia, 2011),, accessed 30 June 2011.

7. FarmaVita.Net, "Croatia — Pharmaceuticals and Biotechnology" (2011),, accessed 29 June 2011.

8. Pliva, "Pliva: History" (Croatia),, accessed 30 June 2011.

9. The Guardian, "US embassy cables: Allegations over Croatian pharmaceutical company deal rebutted" (UK, 2010), accessed 30 June 2011.

10. PETO EVIC, "Croatia Fights Counterfeiting" (Belgium, 2011)., accessed 30 June 2011.

11. Securing Pharma, "Croatian study uncovers counterfeit medicines" (2010), accessed 29 June 2011.

12. V. Stecher et al., 12th Congress of the European Society for Sexual Medicine (Lyon, France, 2009).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here